found Documents:550

37th Annual J.P. Morgan Healthcare Conference

1 item

Location: Westin St. Francis Hotel, San Francisco, CA Presentation Date: Wednesday Jan 9, 2019 Presentation Time: 9:30am PST (12:30pm EST/5:30pm BST) Audio Recording: Please download the accompanying presentation. [audio m

Download Presentation (PDF)

Group, Press Releases, Regulatory Notice | 7 Jan 2019

Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference

1 item

Press Release London: Monday, January 7, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th Annual JP Morgan Healthcare Conference on Wednes

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 31 Dec 2018

Blocklisting Six Monthly Return

1 item

London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 31 Dec 2018

Total Voting Rights

1 item

London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2018, the issued share capital of Chi-Med consisted of 66,657,745 ordinary shares of US$1.00 each

View Announcement (PDF)

Event | 21 Dec 2018

Bloomberg Intelligence - Harnessing China Biotech’s Potential

Bloomberg Hong Kong Office

Event | 21 Dec 2018

Trout Annual 1x1 Management Access Event

Handlery Union Square, San Francisco, CA

Innovation Platform, Press Releases, RNS Announcements | 20 Dec 2018

Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company

1 item

– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China – – Chi-Med to assume all development costs of life cycle indications in

Download Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 20 Dec 2018

Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy

1 item

– Global SAVANNAH study of savolitinib / Tagrisso®combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showedMET-amplification among the most frequent mechanisms of acquired resistance to AstraZeneca’s Tagrisso® – – China

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 14 Dec 2018

TR-1: Form for notification of major holdings

1 item

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 30 Nov 2018

Total Voting Rights

1 item

London: Friday, November 30, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2018, the issued share capital of Chi-Med consisted of 66,623,441 ordinary shares of US$1.00 each

View Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 29 Nov 2018

Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors

1 item

London: Thursday, November 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib (HMPL-012 or sulfatinib) a

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 26 Nov 2018

Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)

1 item

London: Monday, November 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate®) with the initiation of product sales in China. Elunate® is for the

Download Press Release (PDF)

Event | 22 Nov 2018

Goldman Sachs Asia Pacific Healthcare Forum 2018

JW Marriott Hotel, Hong Kong

Innovation Platform | 20 Nov 2018

Chi-Med Receives BayHelix R&D Achievement of the Year Award at BioCentury China Healthcare Summit

1 item

Shanghai: November 20, 2018: Hutchison China MediTech (“Chi-Med”) received “R&D Achievement of the Year” Award from BayHelix at the BioCentury China Healthcare Summit on November 14, 2018. Hutchison MediPharma, the Innovation Platform

Download Press Release (PDF)

Innovation Platform, RNS Announcements | 16 Nov 2018

Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

1 item

– Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – London: Friday, November 16, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the outcome of

View Announcement (PDF)

Event | 16 Nov 2018

HSBC China Healthcare Corporate Day

The Ritz-Carlton, Shenzhen

Event | 2 Nov 2018

BioCentury & BayHelix: China Healthcare Summit 2018

Jing An Shangri-La, Shanghai

Event | 2 Nov 2018

Citi China Investor Conference 2018

Grand Hyatt, Macau

Event | 2 Nov 2018

Daiwa Investment Conference Hong Kong 2018

Island Shangri-La Hotel, Hong Kong

Event | 2 Nov 2018

Jefferies 2018 London Healthcare Conference

Waldorf Hilton, Aldwych, London

Event | 1 Nov 2018

FT Global Pharmaceutical and Biotechnology Conference

Royal Lancaster, London, UK

Event | 1 Nov 2018

Credit Suisse China Investment Conference

Futian Shangri-La, Shenzhen

Regulatory Notice, RNS Announcements | 31 Oct 2018

Total Voting Rights

1 item

London: Wednesday, October 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at October 31, 2018, the issued share capital of Chi-Med consisted of 66,618,660 ordinary shares of US$1.00 eac

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 22 Oct 2018

Grant of Share Options under Share Option Scheme

1 item

London: Monday, October 22, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 19, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Mee

View Announcement (PDF)

Innovation Platform, RNS Announcements | 18 Oct 2018

Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China

1 item

London: Thursday, October 18, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in combination with azacitidine, an approved nuc

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 5 Oct 2018

Appointment of HSBC Bank plc as Joint Corporate Broker in London

1 item

London: Friday, October 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect. Panmure Gordon (UK) Limited will co

Download Announcement (PDF)

Event | 6 Sep 2018

Morgan Stanley Global Healthcare Conference 2018

Grand Hyatt, New York

Event | 6 Sep 2018

CLSA Investors' Forum 2018

1 item

Grand Hyatt, Hong Kong

Download Presentation (PDF)

Innovation Platform, RNS Announcements | 5 Sep 2018

Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China

1 item

– Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal cancer and will be marketed as Elunate® – – Elunate® data published in JAMA demonstrated increased overall survival versus placebo – – F

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 31 Aug 2018

Total Voting Rights

1 item

London: Friday, August 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 31, 2018, the issued share capital of Chi-Med consisted of 66,535,683 ordinary shares of US$1.00 each, wi

Download Announcement (PDF)

Interim Reports | 10 Aug 2018

Interim Report 2018

Contents Corporate Information Contents 1 Highlights 2 Chairman’s Statement 7 Financial Review 8 Operations Review 10 Condensed Consolidated Balance Sheets 29 Condensed Consolidated Statements of Op

Regulatory Notice, RNS Announcements | 7 Aug 2018

Grant of Share Options under Share Option Scheme

1 item

London: Tuesday, August 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on August 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meetin

View Announcement (PDF)

Group, RNS Announcements | 27 Jul 2018

Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs

1 item

London: Friday, July 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2018 and updates shareholders on key clinical programs. Fruquinti

View Full Announcement (PDF)

Event, Presentations | 27 Jul 2018

2018 Half-Year Financial Results

1 item

Announcement released: 7am BST (2pm HKT/2am EDT) >> See announcement here Presentation webcast & call: 9am BST (4pm HKT/4am EDT) >> Click here for the webcast US conference call: 9am EDT (2pm BST/9

Download Presentation (PDF)

Innovation Platform, Press Releases, RNS Announcements | 23 Jul 2018

Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States

1 item

London: Monday, July 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic neuroendocrine tumors (“NET”) patients and in biliary tract cancer (�

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 29 Jun 2018

Total Voting Rights

1 item

London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 29, 2018, the issued share capital of Chi-Med consisted of 66,532,683 ordinary shares of US$1.00 each, with e

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 29 Jun 2018

Blocklisting Six Monthly Return

1 item

London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (a)

Download Announcement (PDF)

Group, Press Releases, RNS Announcements | 29 Jun 2018

Chi-Med to Announce 2018 Half-Year Financial Results

1 item

London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST). An analy

Download Announcement (PDF)

Presentations | 26 Jun 2018

JAMA: Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer

The FRESCO Randomized Clinical Trial Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng; Zhen-dong Chen; Haijun Zhong; Hongming Pan; Weijian Guo; Yongqian Shu; Ying Yuan; Jianfeng Zhou; Nong Xu; Tianshu Liu;

Regulatory Notice, RNS Announcements | 7 Jun 2018

Grant of Share Options under Share Option Scheme

1 item

London: Thursday, June 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on June 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting i

View Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 4 Jun 2018

Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting

1 item

Press Release – Chi-Med makes additional FRESCO presentations at ASCO 2018, following oral presentation at ASCO 2017 showing that study met all endpoints with a manageable safety profile and lower off-target toxicities compared to other targeted t

Download Press Release (PDF)

Presentations | 4 Jun 2018

ASCO 2018: Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO

Presenter: Yu-Xian Bai Other Authors: Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua Fan, Jian-Ming Xu, Lin Shen Time & Location: Sunday, June 3, 08:00 – 11:30 CDT; Hall A, Poster Board: #37 Session: Gastrointest

Presentations | 4 Jun 2018

ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO

Presenter: Ruihua Xu Other Authors: Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Y

Regulatory Notice, RNS Announcements | 31 May 2018

Total Voting Rights

1 item

London: Thursday, May 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2018, the issued share capital of Chi-Med consisted of 66,515,756 ordinary shares of US$1.00 each, with e

Download Announcement (PDF)

Group, Press Releases, RNS Announcements | 11 May 2018

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference

Press Release London: Friday, May 11, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of America Merrill Lynch 2018 Health Care Confe

Regulatory Notice, RNS Announcements | 30 Apr 2018

Total Voting Rights

1 item

London: Monday, April 30, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 30, 2018, the issued share capital of Chi-Med consisted of 66,484,620 ordinary sh

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 27 Apr 2018

Results of AGM Meeting

1 item

London: Friday, April 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2018 were duly pa

Download Announcement (PDF)

Regulatory Notice, RNS Announcements | 23 Apr 2018

Block Admission

1 item

London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,425,597 ordinary shares, par value of US$

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 23 Apr 2018

Grant of Share Options under Share Option Scheme

1 item

London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on April 20, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting

View Announcement (PDF)

Event | 18 Apr 2018

Bank of America Merrill Lynch Health Care Conference 2018

Location: The Encore, Las Vegas, NV, United States Time: 1:00 pm PDT >> Click here for the webcast

2 3 4 5 6 7 8 9 10 11